Kyntheum

Kyntheum Uses, Dosage, Side Effects, Food Interaction and all others data.

Kyntheum has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Kyntheum was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.

Increase in the level of IL-17 due to blocking of its receptors.

Table Of contents

• Kyntheum
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Kyntheum
Availability	Prescription only
Generic	Brodalumab
Brodalumab Other Names	Brodalumab
Related Drugs	Humira, Otezla, Cosentyx, methotrexate, Enbrel, Remicade, Stelara, cyclosporine, infliximab
Type	Injection
Groups	Approved, Investigational
Therapeutic Class
Manufacturer	Leo Laboratories Limited
Available Country	United Kingdom
Last Updated:	September 19, 2023 at 7:00 am

Uses

Kyntheum is a monoclonal antibody used to treat moderate to severe plaque psoriasis.

Kyntheum has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma.

Kyntheum is also used to associated treatment for these conditions: Severe Plaque psoriasis, Moderate Plaque psoriasis

How Kyntheum works

Kyntheum binds with high affinity to interleukin (IL)-17 receptor A, thereby inhibiting several pro-inflammatory cytokines from the IL-17 family.

Food Interaction

No interactions found.

Kyntheum Disease Interaction

Major: Crohn's disease, depression, tuberculosis, vaccinationModerate: infections

Volume of Distribution

4.62 L.

Clearance

0.223 L/day.

Innovators Monograph

You find simplified version here Kyntheum